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Adoptive T-cell therapies for cancer can induce tumor
responses in patients with metastatic melanoma, synovial
sarcoma, and B-cell malignancies. However, no cellular
therapy has demonstrated activity in a common epithelial
tumor. Adoptive transfer of tumor infiltrating lymphocytes
(TIL) has high response rates and can induce complete
and durable tumor regression in metastatic melanoma.
We sought to determine the objective tumor response
rate of TIL therapy for human papillomavirus (HPV)-
associated malignancies. These common epithelial cancers
occur at varied sites but universally express the immuno-
genic E6 and E7 viral oncoproteins making them rational
targets for T cell-based therapeutic approaches. Herein we
report the results of treatment of the first eight subjects
(seven evaluable) from the cohort of patients with cervical
cancer (which is necessarily associated with high-risk HPV
infection) treated with TIL therapy. Tumors were HPV
genotyped and TIL were generated from individual tumor
fragment cultures then tested for reactivity against autolo-
gous dendritic cells loaded with pools of overlapping pep-
tides spanning type-specific HPV E6 or E7 proteins.
Cultures were selected for rapid expansion and adminis-
tration to patients based on oncoprotein reactivity, T-cell
growth rate, and CD8+ T cell frequency. Patients received
non-myeloablative lymphoconditioning chemotherapy
before cell infusion and high-dose bolus IL-2 after cell
infusion. TIL from 6/8 patients displayed reactivity against
E6 or E7. Objective tumor responses by RECIST criteria
were observed in 3/7 evaluable patients; two have com-
plete and ongoing regression of measurable disease at
three and nine months after treatment. Adverse events
were the expected combined toxicities of the preparative
chemotherapy regimen and interleukin-2, and were con-
sistent with those of TIL therapy for metastatic melanoma.
No autoimmunity was observed. These early clinical trial
results indicate that tumor responses can occur following
administration of TIL for metastatic cervical cancer.
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